New hope for tough stomach cancers: testing a powerful drug duo
Disease control
Not yet recruiting
This study is testing a new combination of two immunotherapy drugs (Iparomlimab/Tuvonralimab) with a chemotherapy drug for people with advanced stomach or gastroesophageal junction cancer. It's for patients whose cancer has continued to grow or who couldn't tolerate their first s…
Phase: NA • Sponsor: Qingxia Li • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC